Trial Outcomes & Findings for A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome (NCT NCT03005327)

Last Updated: 2024-10-30

Results Overview

AUCANC was collected over a 24-hour period above clinically meaningful thresholds for the mavorixafor-treated participants over 6 months. The absolute neutrophil count (ANC) clinically meaningful threshold was defined as ANC ≥ 600/microliter (μL).

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

8 participants

Primary outcome timeframe

Time 0 (-15 minutes [min] pre-dose), 30, 60, and 90 min (each ± 5 min) and 2, 3, 4, 8, 12, 16, and 24 hours (each ±15 min) at Weeks 5, 13, and 21

Results posted on

2024-10-30

Participant Flow

Each participant was treated at doses that were increased up to a maximum total daily dose of 400 milligrams (mg) based on their individual area under the curve for absolute neutrophil count and absolute leukocyte count (AUCANC/ALC) values.

Participant milestones

Participant milestones
Measure	X4P-001 50 to up to 400 mg/kg Participants received X4P-001 (mavorixafor) orally once daily (QD) at doses between 50 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a treatment-limiting toxicity (TLT) event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.	X4P-001 100 to up to 400 mg/kg Participants received X4P-001 (mavorixafor) orally QD at doses between 100 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a TLT event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.	X4P-001 200 to up to 400 mg/kg Participants received X4P-001 (mavorixafor) orally QD at doses between 200 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a TLT event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.	X4P-001 300 to up to 400 mg/kg Participants received X4P-001 (mavorixafor) orally QD at doses between 300 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a TLT event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.
Initial Treatment Period (24 Weeks) STARTED	2	2	2	2
Initial Treatment Period (24 Weeks) Received at Least 1 Dose of Study Drug	2	2	2	2
Initial Treatment Period (24 Weeks) COMPLETED	2	1	1	2
Initial Treatment Period (24 Weeks) NOT COMPLETED	0	1	1	0
Extension Phase (56 Months) STARTED	2	0	1	2
Extension Phase (56 Months) COMPLETED	2	0	1	2
Extension Phase (56 Months) NOT COMPLETED	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	X4P-001 50 to up to 400 mg/kg Participants received X4P-001 (mavorixafor) orally once daily (QD) at doses between 50 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a treatment-limiting toxicity (TLT) event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.	X4P-001 100 to up to 400 mg/kg Participants received X4P-001 (mavorixafor) orally QD at doses between 100 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a TLT event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.	X4P-001 200 to up to 400 mg/kg Participants received X4P-001 (mavorixafor) orally QD at doses between 200 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a TLT event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.	X4P-001 300 to up to 400 mg/kg Participants received X4P-001 (mavorixafor) orally QD at doses between 300 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a TLT event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.
Initial Treatment Period (24 Weeks) Adverse Event	0	0	1	0
Initial Treatment Period (24 Weeks) Withdrawal by Subject	0	1	0	0

Baseline Characteristics

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	X4P-001 n=8 Participants Participants received X4P-001 (mavorixafor) orally QD at doses between 50 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a TLT event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.
Age, Continuous	35.5 years STANDARD_DEVIATION 13.37 • n=99 Participants
Sex: Female, Male Female	6 Participants n=99 Participants
Sex: Female, Male Male	2 Participants n=99 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=99 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	8 Participants n=99 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=99 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=99 Participants
Race (NIH/OMB) Asian	0 Participants n=99 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=99 Participants
Race (NIH/OMB) Black or African American	0 Participants n=99 Participants
Race (NIH/OMB) White	8 Participants n=99 Participants
Race (NIH/OMB) More than one race	0 Participants n=99 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=99 Participants

PRIMARY outcome

Timeframe: Time 0 (-15 minutes [min] pre-dose), 30, 60, and 90 min (each ± 5 min) and 2, 3, 4, 8, 12, 16, and 24 hours (each ±15 min) at Weeks 5, 13, and 21

Population: Overall Number of Participants Analyzed=number of participants in safety population (all participants who received at least 1 dose of study medication). 'Number analyzed'=number of participants with data above clinically meaningful thresholds at specified timepoints. Participants included in 1 category may be different than participants in other categories. Data for this Outcome Measure were collected by dose level; therefore, participants may have been included in more than 1 arm (dose level).

Outcome measures

Outcome measures
Measure	X4P-001 50 mg n=2 Participants Participants received X4P-001 50 mg orally QD.	X4P-001 100 mg n=2 Participants Participants received X4P-001 100 mg orally QD.	X4P-001 150 mg n=2 Participants Participants received X4P-001 150 mg orally QD.	X4P-001 200 mg n=2 Participants Participants received X4P-001 200 mg orally QD.	X4P-001 300 mg n=4 Participants Participants received X4P-001 300 mg orally QD.	X4P-001 400 mg Participants received X4P-001 400 mg orally QD.	X4P-001 300/400 mg n=4 Participants Participants received X4P-001 300 mg or 400 mg orally QD.
Mean Value of the Area Under the Plasma Concentration-time Curve for Absolute Neutrophil Count (AUCANC) Week 5	-12574.63 cells*hour/μL Standard Deviation 156.094	-6206.75 cells*hour/μL Standard Deviation 4238.280	—	-6949.58 cells*hour/μL	24175.00 cells*hour/μL Standard Deviation 777.817	—	24175.00 cells*hour/μL Standard Deviation 777.817
Mean Value of the Area Under the Plasma Concentration-time Curve for Absolute Neutrophil Count (AUCANC) Week 13	—	-11291.96 cells*hour/μL Standard Deviation 1509.496	—	-7575.21 cells*hour/μL Standard Deviation 2701.443	-2602.50 cells*hour/μL	—	-2602.50 cells*hour/μL
Mean Value of the Area Under the Plasma Concentration-time Curve for Absolute Neutrophil Count (AUCANC) Week 21	—	—	-8723.00 cells*hour/μL Standard Deviation 2695.962	—	58118.02 cells*hour/μL Standard Deviation 112851.505	—	58118.02 cells*hour/μL Standard Deviation 112851.505

PRIMARY outcome

Timeframe: Time 0 (-15 min pre-dose), 30, 60, and 90 min (each ± 5 min) and 2, 3, 4, 8, 12, 16, and 24 hours (each ±15 min) at Weeks 5, 13, and 21

Population: The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

AUCANC was collected over a 24-hour period above clinically meaningful thresholds for the mavorixafor-treated participants over 6 months. The ANC clinically meaningful threshold was defined as ANC ≥ 600/μL. Data for this outcome measure are reported as an "All Visits" summary based on the mean of AUCs that is, the per-participant average of the AUCANC across the 3 visits where participant was treated with at least 300/400 mg dose. Time frame reported is based on data collection time points.

Outcome measures

Outcome measures
Measure	X4P-001 50 mg n=5 Participants Participants received X4P-001 50 mg orally QD.	X4P-001 100 mg Participants received X4P-001 100 mg orally QD.	X4P-001 150 mg Participants received X4P-001 150 mg orally QD.	X4P-001 200 mg Participants received X4P-001 200 mg orally QD.	X4P-001 300 mg Participants received X4P-001 300 mg orally QD.	X4P-001 400 mg Participants received X4P-001 400 mg orally QD.	X4P-001 300/400 mg Participants received X4P-001 300 mg or 400 mg orally QD.
All Visits: Average Per-Participant Value of the AUCANC	27477.00 cells*hour/μL Standard Deviation 55792.377	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Time 0 (-15 min pre-dose), 30, 60, and 90 min (each ± 5 min) and 2, 3, 4, 8, 12, 16, and 24 hours (each ±15 min) at Weeks 5, 13, and 21

AUCALC was collected over a 24-hour period above clinically meaningful thresholds for the mavorixafor-treated participants over 6 months. The absolute lymphocyte count (ALC) clinically meaningful threshold was defined as ALC ≥ 1000/μL.

Outcome measures

Outcome measures
Measure	X4P-001 50 mg n=2 Participants Participants received X4P-001 50 mg orally QD.	X4P-001 100 mg n=2 Participants Participants received X4P-001 100 mg orally QD.	X4P-001 150 mg n=2 Participants Participants received X4P-001 150 mg orally QD.	X4P-001 200 mg n=2 Participants Participants received X4P-001 200 mg orally QD.	X4P-001 300 mg n=4 Participants Participants received X4P-001 300 mg orally QD.	X4P-001 400 mg Participants received X4P-001 400 mg orally QD.	X4P-001 300/400 mg n=4 Participants Participants received X4P-001 300 mg or 400 mg orally QD.
Mean Value of the Area Under the Plasma Concentration-time Curve for Absolute Lymphocyte Count (AUCALC) Week 5	-5839.54 cells*hour/μL Standard Deviation 6485.407	6978.25 cells*hour/μL Standard Deviation 7435.935	—	4783.33 cells*hour/μL	21837.50 cells*hour/μL Standard Deviation 24236.085	—	21837.50 cells*hour/μL Standard Deviation 24236.085
Mean Value of the Area Under the Plasma Concentration-time Curve for Absolute Lymphocyte Count (AUCALC) Week 13	—	-1006.50 cells*hour/μL Standard Deviation 10546.262	—	7023.83 cells*hour/μL Standard Deviation 1603.482	2862.50 cells*hour/μL	—	2862.50 cells*hour/μL
Mean Value of the Area Under the Plasma Concentration-time Curve for Absolute Lymphocyte Count (AUCALC) Week 21	—	—	-2216.17 cells*hour/μL Standard Deviation 8285.642	—	15331.35 cells*hour/μL Standard Deviation 21250.202	—	15331.35 cells*hour/μL Standard Deviation 21250.202

PRIMARY outcome

Timeframe: Time 0 (-15 min pre-dose), 30, 60, and 90 min (each ± 5 min) and 2, 3, 4, 8, 12, 16, and 24 hours (each ±15 min) at Weeks 5, 13, and 21

AUCALC was collected over a 24-hour period above clinically meaningful thresholds for the mavorixafor-treated participants over 6 months. The ALC clinically meaningful threshold was defined as ALC ≥ 1000/μL. Data for this outcome measure are reported as an "All Visits" summary based on the mean of AUCs that is, the per-participant average of the AUCALC across the 3 visits where participant was treated with at least 300/400 mg dose. Time frame reported is based on data collection time points.

Outcome measures

Outcome measures
Measure	X4P-001 50 mg n=5 Participants Participants received X4P-001 50 mg orally QD.	X4P-001 100 mg Participants received X4P-001 100 mg orally QD.	X4P-001 150 mg Participants received X4P-001 150 mg orally QD.	X4P-001 200 mg Participants received X4P-001 200 mg orally QD.	X4P-001 300 mg Participants received X4P-001 300 mg orally QD.	X4P-001 400 mg Participants received X4P-001 400 mg orally QD.	X4P-001 300/400 mg Participants received X4P-001 300 mg or 400 mg orally QD.
All Visits: Average Per-Participant Value of the AUCALC	14232.17 cells*hour/μL Standard Deviation 16789.700	—	—	—	—	—	—

PRIMARY outcome

Timeframe: From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days)

Population: The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). Data for this Outcome Measure were collected by dose level; therefore, participants may have been included in more than one arm (dose level).

An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A TEAE was defined as any AE that began or worsened in severity or frequency on or after the start of study drug through 10 days after the last dose of the study drug. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.

Outcome measures

Outcome measures
Measure	X4P-001 50 mg n=2 Participants Participants received X4P-001 50 mg orally QD.	X4P-001 100 mg n=4 Participants Participants received X4P-001 100 mg orally QD.	X4P-001 150 mg n=3 Participants Participants received X4P-001 150 mg orally QD.	X4P-001 200 mg n=4 Participants Participants received X4P-001 200 mg orally QD.	X4P-001 300 mg n=7 Participants Participants received X4P-001 300 mg orally QD.	X4P-001 400 mg n=5 Participants Participants received X4P-001 400 mg orally QD.	X4P-001 300/400 mg n=8 Participants Participants received X4P-001 300 mg or 400 mg orally QD.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	2 Participants	2 Participants	2 Participants	2 Participants	6 Participants	3 Participants	7 Participants

Adverse Events

X4P-001 50 mg

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

X4P-001 100 mg

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

X4P-001 150 mg

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

X4P-001 200 mg

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

X4P-001 300 mg

Serious events: 2 serious events

Other events: 6 other events

Deaths: 0 deaths

X4P-001 400 mg

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

Overall Participants

Serious events: 3 serious events

Other events: 7 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	X4P-001 50 mg n=2 participants at risk Participants received X4P-001 50 mg orally QD.	X4P-001 100 mg n=4 participants at risk Participants received X4P-001 100 mg orally QD.	X4P-001 150 mg n=3 participants at risk Participants received X4P-001 150 mg orally QD.	X4P-001 200 mg n=4 participants at risk Participants received X4P-001 200 mg orally QD.	X4P-001 300 mg n=7 participants at risk Participants received X4P-001 300 mg orally QD.	X4P-001 400 mg n=5 participants at risk Participants received X4P-001 400 mg orally QD.	Overall Participants n=8 participants at risk Participants received X4P-001 (mavorixafor) orally QD at doses between 50 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a TLT event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.
General disorders Pyrexia	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Bronchitis	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Cellulitis	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Influenza	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Tibia fracture	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).

Other adverse events

Other adverse events
Measure	X4P-001 50 mg n=2 participants at risk Participants received X4P-001 50 mg orally QD.	X4P-001 100 mg n=4 participants at risk Participants received X4P-001 100 mg orally QD.	X4P-001 150 mg n=3 participants at risk Participants received X4P-001 150 mg orally QD.	X4P-001 200 mg n=4 participants at risk Participants received X4P-001 200 mg orally QD.	X4P-001 300 mg n=7 participants at risk Participants received X4P-001 300 mg orally QD.	X4P-001 400 mg n=5 participants at risk Participants received X4P-001 400 mg orally QD.	Overall Participants n=8 participants at risk Participants received X4P-001 (mavorixafor) orally QD at doses between 50 mg and 400 mg for the Initial Treatment Period (24 weeks) and could continue participation in the open-label Extension Phase until experiencing a TLT event, X4P-001 was available commercially, or until the study was terminated by the Sponsor.
Infections and infestations Genital herpes simplex	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Hordeolum	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Infected bite	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Ear and labyrinth disorders Eustachian tube obstruction	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
General disorders Nodule	50.0% 1/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Ear and labyrinth disorders Otorrhoea	50.0% 1/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Eye disorders Conjunctivitis allergic	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Gastrointestinal disorders Abdominal pain	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 1/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Gastrointestinal disorders Aphthous ulcer	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Gastrointestinal disorders Dry mouth	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 1/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	33.3% 1/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 2/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Gastrointestinal disorders Dyspepsia	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 1/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	40.0% 2/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	37.5% 3/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Gastrointestinal disorders Nausea	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	50.0% 2/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	28.6% 2/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	50.0% 4/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
General disorders Chills	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
General disorders Pyrexia	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Hepatobiliary disorders Cholecystitis	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Arthritis infective	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Bronchitis	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations COVID-19	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Cellulitis	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	40.0% 2/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 2/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Conjunctivitis	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	33.3% 1/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Ear infection	50.0% 1/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Folliculitis	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Papilloma viral infection	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	33.3% 1/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Pharyngitis	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 2/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Localised infection	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Pneumonia	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Lower respiratory tract infection	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Nasopharyngitis	50.0% 1/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	28.6% 2/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 2/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Otitis media	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	40.0% 2/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	37.5% 3/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Otitis media acute	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Viral infection	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Respiratory tract infection	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Sinusitis	50.0% 1/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	28.6% 2/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	40.0% 2/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	37.5% 3/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Skin infection	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Infections and infestations Upper respiratory tract infection	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	28.6% 2/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	37.5% 3/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Animal bite	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Animal scratch	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	33.3% 1/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Incision site ulcer	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Limb injury	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	33.3% 1/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Muscle strain	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Post procedural contusion	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Procedural pain	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Scratch	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 1/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 1/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 2/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	33.3% 1/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Skin and subcutaneous tissue disorders Skin irritation	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Musculoskeletal and connective tissue disorders Temporomandibular joint syndrome	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	20.0% 1/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Reproductive system and breast disorders Uterine spasm	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	33.3% 1/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Reproductive system and breast disorders Vulva cyst	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Respiratory, thoracic and mediastinal disorders Nasal dryness	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 1/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	33.3% 1/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Respiratory, thoracic and mediastinal disorders Rales	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Respiratory, thoracic and mediastinal disorders Wheezing	50.0% 1/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Skin and subcutaneous tissue disorders Dermatitis psoriasiform	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 1/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Skin and subcutaneous tissue disorders Erythema	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 1/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Skin and subcutaneous tissue disorders Palmar erythema	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	25.0% 1/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/2 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/3 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/4 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	14.3% 1/7 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	0.00% 0/5 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).	12.5% 1/8 • From first dose of study drug through 10 days after the last dose of the study drug (Maximum exposure: 1712 days) The Safety Population included all participants who received at least 1 dose of the study medication (mavorixafor). All-Cause Mortality and Adverse Event data were collected by dose level; therefore, participants may have been included in more than one arm (dose level).

Additional Information

Chief Medical Officer

X4 Pharmaceuticals

Phone: (857) 529-8300

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place